Welcome to the ATS Corporation Fourth Quarter Conference Call and Webcast. This call is being recorded on May 16th, 2024 at 8:30 A.M. Eastern Time. Following the presentation, we will conduct a question-and-answer session. I'd now like to turn the call over to David Galison, Head of Investor Relations at ATS. You may now go ahead.

Thank you, operator, and good morning, everyone. On the call today are Andrew Hider, Chief Executive Officer of ATS; and Ryan McLeod, Chief Financial Officer. Please note that our remarks today are accompanied by a slide deck, which can be viewed via our webcast and available at atsautomation.com. We caution that the statements made on the webcast and conference call may contain forward-looking information, and our cautionary statement regarding such information, including the material factors that could cause actual results to differ materially from the statements and the material factors or assumptions applied in making the statements, are detailed on Slide 2 of the slide deck. Now it's my pleasure to turn the call over to Andrew.

Thank you, David. Good morning, everyone, and thank you for joining us. Today ATS reported our fourth quarter and annual results. For the fiscal year as a whole, ATS drove profitable growth, supported by the highest revenues and earnings in company history. In the fourth quarter, we delivered one of our strongest bookings quarters on record along with record revenues. Adjusted earnings were in line with our expectations. Our value creation strategy is being advanced as we completed four acquisitions during fiscal '24 and continued to invest in innovation, increasing our patent portfolio by almost 10% over last year. In addition, we have been active with our share buyback program since late March, having deployed $45 million to repurchase just over 1 million shares. The results reported today reflect the importance of deploying our strategy and our chosen markets, along with our team's commitment to the ABM as we drive continuous improvement throughout our global operations. This morning I will update you on the business and our markets, and then Ryan will provide his financial report. Starting with our financial value drivers. Order bookings for the quarter were $791 million, supported by organic growth in Life Sciences, Food & Beverage, and Energy. The underlying trends driving demand for ATS solutions remain favorable. For the full year, bookings were $2.9 billion. Q4 revenues were $792 million, up 8% from Q4 last year, including organic growth of 4%, along with our first full quarter of Avidity results. For the full year, revenues increased by 18%. Adjusted earnings from operations in Q4 were $96 million. Full year adjusted earnings were $398 million, up 16% compared to fiscal '23. Moving to our outlook. Our backlog remains strong at $1.8 billion. By market, Life Sciences backlog was $871 million, 14% higher than Q4 last year…

Thank you, Andrew, and good morning, everyone. ATS delivered solid financial results this quarter and we finished the year with a strong balance sheet and backlog that provides good revenue visibility for fiscal 2025. Starting with our operating results for the quarter, order bookings were $791 million, up 7.3% compared to Q4 last year. Year-over-year growth was led by Life Sciences with strong organic growth in bookings as well as contributions from our recent acquisitions, including Avidity. Our trailing 12-month book-to-bill ratio at the end of Q4 was 0.95 to 1. Excluding transportation, our trailing 12-month book-to-bill ratio was 1.12 with all other market verticals above one. Q4 revenues were $792 million, up 8.3% over Q4 last year, driven by an increase in Life Sciences revenues of 15.6%. Organic revenue growth was 3.5% in the quarter, while recently acquired companies added approximately 5% growth. Revenues were higher than we had expected at the outset of the fourth quarter as our teams were able to offset headwinds from the delayed EV projects with incremental site support work complemented by strong execution in our Life Sciences business. We finished Q4 with just under $1.8 billion of order backlog. Looking ahead, our revenue conversion for Q1 is estimated to be in the 36% to 40% range of order backlog. As a reminder, this assessment is updated every quarter based on revenue expectations from the existing backlog and new orders booked and billed within the quarter. This conversion range also factors an impact approximately $150 million of Transportation order backlog with one of our EV customers that remains delayed. For fiscal '25 despite expected lower revenues from EV, our business is well positioned to drive top-line growth in our other markets, including our largest market Life Sciences. We expect this growth combined with the…

Thank you very much. We are now opening the floor for a question-and-answer session. [Operator Instructions] Our first question comes from David Ocampo from Cormark Securities. Your line is now open.

Thanks. Good morning, everyone. I guess my first question, Andrew, I mean, the large enterprise EV program that you have was reduced by $50 million, and you guys have made, you know, some pretty significant investments over the last two years to support that program in terms of investments and even working capital. I'm curious if there's any recourse for the adjustments and delays to your customer.

We're having some, sorry, David, did you hear that response or?

No, I did not.

Okay. We're having some technical challenge here. So, sorry, you asked about the cancellation. So under the terms of the contract, you know, customers are responsible for compensating us up until the point of when the work is stopped and canceled. So call it a normal course scope change, and this happens fairly regularly in our business. So in terms of investment, I mean, I think you identified it. It's primarily working capital and our expectations will recover that as part of this cancellation.

Got you. Got you. And I guess, curious if you see any potential risk of a further reduction just given the ongoing softness that we're seeing with EV demand.

Well, I mean, that's not our expectation. You know, in addition to the descoping that happened in the quarter, the net overall program continued to increase. The piece that was descoped or cancelled, I mean, it was in the design phase fairly early on. And so from a customer investment standpoint, it was a -- call it an easier decision to make that change, but I mean, you know, I don't expect further cancellations. Normal core scope changes that that happens, and that's happened more frequently in EV, but, you're right, cancellations, as I think we've talked about in the past are unusual.

Okay. And then my last question, Ryan, is probably better suited to you view, but net working capital was pretty bloated in the quarter, I think closer to 19%. And understanding a lot of that has to do with timing of payments as it relates to EV. Are there any milestone payments that we should be aware of over the next few months that could push that working capital to more normal levels?

Yeah, there are, but I mean, we've seen, I mean, first, some of those are going to push out into further quarters and they're based on the restart and then normal course as projects are getting finalized and ramped up. We'll start to see those milestones, I mean, more, going to be into the Q2, Q3 timeframe, but we are approaching those milestones.

Okay. That's all I have for you guys. Thank you so much.

Thank you, David.

Next question comes from Michael Doumet from Scotiabank. Your line is now open.

Hey, good morning, guys. I'm just curious on why the commentary on the revenue outlook excludes the revised EV order. You know, is it just reflecting of uncertainty around timing? And then on the commentary on the outlook as far as the Transportation funnel, your outlook indicates that some of the large orders, effectively not all the large orders have moved further into the future. I mean, is there an expectation that you could potentially close another large order in the near term?

So I'll start. Good morning, Michael. I mean, we've really taken that out of our expectation really just tied to timing. It's something and Andrew talked about it, it could restart in Q1 or staying very close with the customer, but we've taken it in our outlook because there is uncertainty around that timing. And I'll let Andrew talk about to that point.

Yeah, and to add on to that, Michael. So there's two key areas this customer is focused on, and it is the customer indication of when this will restart with these two key areas. First, it's really around the battery technology that they plan to move forward with and then second, end market demand. And so, we obviously have very, very frequent ongoing conversations both on the work we're involved in as well as this application. So we took it off and it will be largely offset with growth in other areas. And so we're setting the business up really around the timing of the business and this program. And if the delay comes back online, it will be additive to our expectations. As far as your second part of the question in the business and the market, just a couple of comments on this. First, we won't work in the quarter and we continue to engage customers. We do view their approach is going to be a bit more measured in the short-term. Measured means they're looking at their technology, they're looking at their market demand, and realigning their expectations around investment for that. And so we continue to see opportunities. We've set the business up and we can be patient in the situation we sit in today. We've taken the right action to set ourselves up and we continue to see strength in other parts of our business. So long-term, when we step back and look at EV, the market is slated to grow, call it double every 2.5 years, 2 to 2.5 years. And ATS has strong value and it is an organic area focus for us. So relatively muted, relatively low investment, strong return, and we take that return and put it in other areas of the business and continue to grow.

Very helpful, guys. Thanks. And then for the next quarter, should we expect somewhat of like a similar margin impact given the deferral so far and maybe just a high-level question, assuming declines in transportation, how are you guys thinking about managing labor and overhead in the near term to shield yourself some potential margin variability given that the outlook still kind of remains potentially quite favorable in the longer term?

Yes. So we've aligned the business or cost structure to meet the current levels of demand. And with that said, we're always going to monitor and if further adjustments are required, we'll do that. In terms of our margin outlook, part of how we were able to offset the headwinds in this quarter were tied to on-site support work, and that work is continuing. Now we do expect that to tail off again as these projects get ramped up on site of customers. In the fourth quarter, I did talk about some lower-margin programs that impacted our gross margin -- gross margin, sorry. Those are largely behind us. And from an SG&A standpoint, sequentially we have a little bit of additional spend really tied to people costs, and that will be more normalized through it next year. So from a margin standpoint, we don't expect any headwinds going into next fiscal year.

Very helpful. I'll pass the line. Thanks guys.

Our next question comes from Joe Ritchie from Goldman Sachs. Your line is now open.

Thanks. Good morning, everybody.

Good morning.

Good morning.

Can we just touch on the autoinjector ramp over the next several years getting to the high-single-digits portion of your revenue? I just want some clarification on that. Is there an expectation that in fiscal '25 you'll get there? And if not, maybe just talk to us a little bit about like how you expect that ramp to go in the coming years.

Yeah, Joe. So I'll start. So this has been the last couple of quarters, high single-digit and low double-digit percentage of our overall bookings. So it's been a strong area of growth for our bookings. We've started these programs, they're 12 to 14 months kind of on average. So we're getting into higher revenue phases. And so we're going to see that, that revenue contribution move from where it was in '24 low-single-digits, up into that high-single-digits in quarters, we'll get into double-digits. But that's how the backlog to revenue is going to unfold.

Yeah, and Joe, just to add a little bit more color on this area, this space. And I know I walked through it in my prepared remarks, more double-digit customers in this area, strong offering with strong capability. And, as a reminder, we've invested in this space and continue to invest in the space. And we've been here even with the EpiPen called two decades, but we've launched with our Symphoni platform, the ability to be, you know, up to double the output of the standard process and half the footprint. So strong capability for customers that are moving into the space and or have gained approvals. And when we see areas like cardiovascular disease or even continued approvals around GLP-1, it really is an area for strike for ATS. Now, all that said, we have many areas that we like in the Life Sciences space, whether it's radiopharmaceuticals or wearable devices or even in the last couple of quarters, we had strong awards from contact lenses. So we see strong tail on GLP-1 drugs and the autoinjector space. And the approvals this year are actually outpacing last year. And so we see for the foreseeable future this being a strong area of focus for ATS.

Got it. That's helpful, guys. Thank you. And then I guess my second question, I really want to focus on free cash flow. And just given that there was an outlay in free cash flow this past year, how do I think about this framework going forward? I know you guys have talked about networking capital, getting down below that mid-teens percentage, but help me understand what the expectations are for 2025 or fiscal year '25 and then beyond.

Yeah. So, I mean the biggest impact on our free cash flow in '24 was working capital, and that's tied to EV. We talked about in the past there being higher variability given the size of these programs. And as we're getting into latter stages, the question, similar questions asked, but we are going to see some of those milestones towards the middle to Q2, Q3 of our fiscal year this year. So our goal, and we talked about it is, is to be in that 15% below range. We've had some inventory builds outside of the specific EV area, but they're pretty small. Overall AR collections have continued to be quite strong. The biggest drivers really been in that EV space. As the business, I'll say the portfolio shifts into next year and we're going to see -- and we talked about larger contributions from Life Sciences, from our Food and Energy businesses, we will see that reflected in lower working capital. But as I said, it's going to be tied to EV milestones and likely in the Q -- or the second half of the fiscal.

Okay. Great. Thank you.

Our next question comes from Michael Glen from Raymond James. Your line is now open.

Hey, good morning. So there's a lot of moving parts taking place in the quarter, but I'm just really interested. Can you give some updated commentary surrounded your target for 15% adjusted EBIT margin? I know there is no time frame for this. But would you say this is still within reach? Is it being pushed out? Just trying to get some indication as to that particular metric.

Yeah, I mean, so, absolutely, that's our target. That goal is unchanged. And, I mean, I'll start with our operations. We've got a number of initiatives. They're well embedded in our business, and they've served us particularly. They served as well. Supply chain, that's been an area that's performed very well, even in challenging conditions over the last, call it, 18 months. We're continuing to make good progress in our after-sales service business, which is accretive. Other areas of focus, such as standardization, are continuing to progress. And standardization is an interesting one, I mean, Andrew mentioned the Symphoni platform, which is the standard technology platform that we're utilizing in the autoinjector space. I mean, that's a great example of how our team is identifying core technology, standardizing, really driving efficiency through the engineering process, through the assembly process. So all of those initiatives are, like I said, well embedded. We're managing our SG&A spend as we're investing in growth areas. We've reduced spend in other areas, and we talked about the reorganization activities we undertook this year. All that said, there's the EV headwind in the short-term from a revenue standpoint. But again, we do expect the growth in our other market verticals to largely offset and support continued margin expansion.

Okay. And I'll ask one on the EV as well. The 150 in delayed, is that -- where is that right now? Is that sitting in your bookings, or is that contained in working capital? That's the 150 of delayed work.

So the 150 is a backlog number, and it is in our backlog. Again, it's contracted. So we haven't removed it from the backlog number, but we have taken it out of our revenue expectations for the year. There's a working capital impact tied to that, but it's smaller. It's much smaller than the 150.

Okay. And the working capital build that we're seeing right now, like as you've said, that is really tied to EV. All the other verticals remain largely where you would want them to be?

Yeah, that's correct. That's correct. And I do -- I would point out some of the acquisitions also change the profile. I mean, not in a material way, but, you know, Avidity, for example, is a high teen, low 20% working capital intensity business. Paxiom is more in line. It's not, obviously, not part of our business yet, but it's in the mid-teens. But some of those shorter cycle businesses typically do have more inventory that's carried the business. And so there'll be areas of opportunity to improve those metrics. But from a portfolio, those do drive a bit of a shift over time.

Okay. Thank you.

[Operator Instructions] Our next question comes from Justin Keywood from Stifel. Your line is now open.

Good morning. Thanks for taking my call. Just on the margin contribution of projects, how should we be looking at GLP-1? Is this at about the same level? Higher or lower?

So at the gross margin line, it's largely in line with our Life Sciences business, Justin. That's typically ahead of where we are from a corporate average standpoint, but not necessarily different from the Life Sciences portfolio.

Okay. Understood. And then on the Paxiom acquisition, 19% EBITDA margins. That's much higher than the Food & Beverage space as the portfolio sits today, I think it's around 10%. Is there anything unique that Paxiom is doing to drive that higher margins? And also, is there any synergy opportunities with that acquisition?

Yeah. So Justin, a couple of items. First, and I want to highlight, we've seen nice progress in the packaging and food technology portfolio. And as a reminder, CFT was low-single-digits and the team is really actually improving the plan on expanding that. So proud of the work being done. But as, you know, Paxiom really aligns well with what we view as longer term on a margin perspective. And just to give you some insight, the business is a very strong brand with the customers they serve. It's highly valued in, not only in the solution, but their capability for servicing and supporting their customers. And so we went through the diligence process and really peeled and really dug into understanding their customer engagement. They have a very strong brand, a very strong name in the space they serve. And so, we're pleased that they've decided to join the team. We've been actually scouting this for, call it, close to two years, actively engaged for over a year around the cultivation activities. And as far as synergies goes, this fits right in line with our business. And first and foremost, it's an offset to seasonality around the harvest season. This is its primary and secondary packaging, which fundamentally means that you're in line on the packaging process. And whether it's MARCO, NCC, CFT, Comecer or IWK, it's squarely in line to offer and add high value as we look at the adjacencies around those spaces. So first and foremost, we need to close and have them add. But I'm very excited about this business being a part of the future for ATS and what it will offer from both a synergy and capability perspective.

Understood. That's very helpful. You answered one of my questions, Paxiom being a cultivated deal. Could you also describe your pipeline for additional transactions if it would be focused in Food & Beverage or other segments? And any other indication as far as target multiples and size of transaction? Thank you.

Yes. So if we step back and I actually talked a little bit about this in the prepared remarks, but to put more meat on the bones here, the funnel is healthy and our teams continue to cultivate. And if you look at the areas we target, we often use the phrase high consequence of failure. And it aligns well with regulated spaces, but also spaces that customers value and often niche applications. So you're going to see us targeting and continue to target Life Sciences applications, food safety applications, digital and services applications around really where we view high value for customers. And once that we can help support and drive synergies and take our supply chain capability and reduce their cost structure, help them reduce their overall spend to drive improvements on the bottom line. So we've seen our funnel continue to grow and be a key area of focus. Multiples have not largely changed. And targeted areas, as we continue to evolve our portfolio, we see future opportunities, and Paxium being just one of those where we think we can continue to expand upon.

Thank you.

Our next question comes from Patrick Baumann from JPMorgan. Your line is now open.

Oh, hi. Good morning. Thanks for taking my questions. Maybe just the first one, if you could help us understand mechanically why backlog was down $100 million or so from the third quarter when the book-to-bill was one times? And I know you mentioned something about like $50 million of descoped business in that EV contract, but the decline sequentially was a bit above that. So just wondering if you can give us some color on why that was.

Yeah. Good morning, Patrick. So that was the biggest impact was that EV cancellation. There was some other normal course scope changes, content gets removed, stations capacity changes, things like that. There was -- were actually two cancellations tied to acquisitions. Now, these were smaller dollars, but businesses that were acquired and projects put on hold. So on that I would call a little bit more unusual, but the rest is really normal course. There were some FX headwinds in the quarter as well. I mean, it's a mixture of things. But overall, again, we said that we're in a good position with our backlog despite that delayed project.

Okay. And then my follow-up is on the 2025 outlook for flat sales. What do you expect the EV sales to be down for the year? I'm just trying to get a sense of how much growth you would need in any other markets to offset it. And then if you could talk about how it profiles because you're sort of guiding, I guess, first quarter down about 10% year-over-year. So just wondering when you expect the growth rate to flip positive to offset the slower start.

Well, from a book-to-bill standpoint, you know, that's probably the best indicator. So as we talked about, Life Sciences was in the 1.13 area on a trailing 12 months. Transportation was 0.58. Consumer, Food both 1.06 and then Energy was 1.4. So organically, I mean, directionally, that's how to think about it. Given project progress where we are on the various -- in the various markets, we do see a bigger ramp in the second half on revenues relative to the first. But of course, that's going to be impacted by what we book over the next couple of quarters and then also by service revenues in the shorter cycle businesses that we have as well. And the other piece on Transportation, these projects are typically 18 to 24 months. So it's not exactly a normal annual book-to-bill cycle, but the rest of the business is, you know, that's the way to think about it.

And Transport being 18 to 24 months, I guess, you're just signaling that not to take the full book-to-bill impact into account for '25. Is that what your message is on that?

Yeah, or said another way, there's more time from a backlog and funnel perspective to replenish that business.

Understood. Okay. Thanks so much for the time.

Next question comes from Maxim Sytchev from National Bank Financial. Your line is now open.

Hi. Good morning, gentlemen.

Good morning.

Good morning

Andrew, maybe just one kind of high-level question as we've seen a couple of protectionist measures being implemented in the US when that comes to tariffs on Chinese EVs, syringes, and that type of stuff. Just curious from a sort of a secular positioning perspective, how do you think this potential actions could be presumably positively impacting ATS down the road? Thanks.

Yeah, Max, whenever there's a regulation around driving North America and European focus, it largely plays a positive for automation, and we would see this as no different. And whether it's onshoring supply chain de-risking, meeting or driving regulation, it pulls in process around building manufacturing in a region that we have a strong position within. And then what you'll generally find is labor shortages, labor cost, lean in even heavier with automation. So we would even largely see it as favorable for ATS and really strong value for what we offer for our customers.

Yes. Makes sense. And then my last question is maybe when you look at potential choices between NCIB versus kind of doing M&A because, I mean, you bought stock at an average, I think it was like $45 a share. How do you think about what makes the most sense now? I mean, like, obviously, I understand that every opportunity is idiosyncratic, but what is your framework of thoughts around these two capital allocation strategies? Thanks.

Yeah. So I don't think so, Max. So in the past, we have been, I'll start with what we've done. So on the NCIB, we've been active. We purchased just over a million shares, deployed about $45 million in capital. So roughly $44 a share is what we've been buying at what we purchased at over the last six, seven, eight weeks now, and then we've also been active on M&A. So it's not really our choice. Now, the NCIB, it is really -- we view it as opportunistic. So we don't have a set allocation in our annual planning. It's opportunistic. It's something we regularly review with the Board from a priority perspective. M&A is going to typically take higher priority, and that's how we look at it. Of course, internal investment is also something that we're very active in funding. And Andrew talked about a lot of the innovation activities that are ongoing, but that's really our approach and how we're thinking about it.

And Max, just to add on, look, we are very aligned, and again, it's an ongoing dialogue with the Board, internal investment, greatest return to Ryan's point, M&A and share buybacks. Obviously, you know, we are in a position to be able to do both. And we continue to drive, you know, a focus on capital allocation to return to shareholders.

Okay. Makes sense. That's it for me. Thanks.

The next question comes from Cherilyn Radbourne from TD. Your line is now open.

Thanks very much and good morning.

Good morning, Cherilyn.

I guess digging through some of the noise in the quarter. What I think you're saying is that basically notwithstanding the weakness in the EV market, you think that the strength ex-EVs plus the acquisition of Paxiom will enable you to deliver revenues that are basically flat to up slightly in fiscal '25. Is that a fair statement? And if it is, can you just give some indication of the level of visibility that you have in those ex-EV markets?

So Cherilyn, I'll start on just to clarify. So we said largely offset, which, certainly, we're going to drive for upside, but at this point, I'd say we're comfortable that we can largely offset the EV headwinds through the growth in other parts of the business and with the addition of Paxiom and a full year contribution from Avidity, which is the other larger and more recent acquisition.

And Cherilyn, to add on the second part of the question. This was the third largest bookings quarter in our history. And if you look at the year, you know, Life Sciences strong performance, 1.13, and Ryan walked through these. But overall, we're pleased in the markets we serve and know that the targets really continue to drive expansion and really alignment to value in those areas of focus. So the end of the quarter, setting up for fiscal '25, really aligned to driving expansion in the markets that we view of high value.

Okay. And so, if we think about that, then the revenue mix by end market should shift favorably in fiscal 2025. You've got supply chain lead times improving, so you should be able to get some purchase efficiencies, and then presumably, you have continued aftermarket growth. So if we sort of combine all of that, is there any reason to think that margins shouldn't be sort of flat to better in fiscal 2025?

You characterized it well. Yeah, I mean, like I said, our long-term goal is margin expansion in a year where top-line is going to be challenged, you know, a flat margin we would be fine with, but our focus is on long-term margin expansion.

Okay. And then, the bookings were obviously a bright spot in the quarter, a big jump versus $668 million last quarter. Can you kind of help us understand the quarter-over-quarter in Delta? And just whether there was anything lumpy in this quarter?

So, yes, I'm hesitating a bit because we always have things I would consider lumpy. But, yeah, I mean, if I look at our Top 10 bookings in the quarter, the average was up sequentially. I'd say the average this quarter was more in line with where we were in Q2. The largest program was in the $50 million, $60 million range, again, similar to where we were in Q2. Q3, the largest, was in the $30 million range, which I would still consider a large program. And I guess I would use the word lumpy on that one too. But, yeah, I mean, Andrew said, we're very pleased with how we finished the year from a bookings perspective. For Top 10, Life Sciences was very strong, but we had good diversity. There was nuclear, there was consumer, there was food in that grouping. So we're quite pleased with -- and EV as well. So we're quite pleased with the diversity in that bookings number.

Okay. Great. Thank you for the time. I'll leave it there.

Thank you, Cherilyn.

There are no further questions. Mr. Hider, back to you for closing comments.

Thank you, operator. We look forward to continuing to execute on our goal of creating shareholder and customer value in fiscal '25. Thanks for joining us today. I look forward to speaking with you on our Q1 call in August. Stay safe and goodbye for now.

Thank you, everyone, for attending today's call. Have a wonderful day. You may now disconnect.